APD125, a Selective Serotonin 5-HT2A Receptor Inverse Agonist, Significantly Improves Sleep Maintenance in Primary Insomnia | Zendy

Russell Rosenberg | Zendy; David Seiden | Zendy; Steven Hull | Zendy; Milton K. Erman | Zendy; Howard Schwartz | Zendy; Christen M. Anderson | Zendy; Warren A. Prosser | Zendy; William Shanahan | Zendy; Matilde Sanchez | Zendy; Emil Chuang | Zendy; Thomas Roth | Zendy

Open Access

APD125, a Selective Serotonin 5-HT2A Receptor Inverse Agonist, Significantly Improves Sleep Maintenance in Primary Insomnia

Author(s) -

Russell Rosenberg,

David Seiden,

Steven Hull,

Milton K. Erman,

Howard Schwartz,

Christen M. Anderson,

Warren A. Prosser,

William Shanahan,

Matilde Sanchez,

Emil Chuang,

Thomas Roth

Publication year - 2008

Publication title -

sleep

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.222

H-Index - 207

eISSN - 1550-9109

pISSN - 0161-8105

DOI - 10.1093/sleep/31.12.1663

Subject(s) - placebo , insomnia , inverse agonist , medicine , agonist , primary insomnia , anesthesia , sleep onset , population , crossover study , polysomnography , psychology , sleep disorder , psychiatry , receptor , alternative medicine , environmental health , apnea , pathology

Insomnia is a condition affecting 10% to 15% of the adult population and is characterized by difficulty falling asleep, difficulty staying asleep, or nonrestorative sleep, accompanied by daytime impairment or distress. This study evaluates APD125, a selective inverse agonist of the 5-HT(2A) receptor, for treatment of chronic insomnia, with particular emphasis on sleep maintenance. In phase 1 studies, APD125 improved sleep maintenance and was well tolerated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research